Control Bionics Reports Revenue Growth, Reaffirms 50% FY27 Growth Outlook
CBL: $0.049 +0.00% · MC: $29M
Control Bionics said unaudited revenue rose each month in the September quarter and exceeded the June quarter, while it expects revenue growth of approximately 50% in FY27, weighted to the second half. Quarterly operating cash outflows included FY26 incentives and other one-off costs, with the company forecasting a material reduction in the next quarter; it reported cash at bank of approximately $6 million at quarter end and said its current plan funds operations through FY27 without another capital raising. Separately, it established a facility for eligible small shareholders to sell their holdings without brokerage or handling fees, with the company covering transaction costs.

Comments